RVL Pharmaceuticals plc Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
RVL Pharmaceuticals plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q2 2023.
  • RVL Pharmaceuticals plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $232K, a 80.8% decline year-over-year.
  • RVL Pharmaceuticals plc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $2.21M, a 68.4% decline year-over-year.
  • RVL Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2022 was $3.9M, a 42.6% decline from 2021.
  • RVL Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2021 was $6.8M, a 51.1% increase from 2020.
  • RVL Pharmaceuticals plc annual Share-based Payment Arrangement, Expense for 2020 was $4.5M, a 12.5% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $2.21M $232K -$977K -80.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $3.19M $499K -$710K -58.7% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $3.9M $724K -$116K -13.8% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-20
Q3 2022 $4.02M $758K -$3M -79.8% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $7.01M $1.21M +$78K +6.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $6.94M $1.21M +$135K +12.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $6.8M $840K -$160K -16% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 $6.96M $3.76M +$2.46M +189% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $4.51M $1.13M -$69K -5.75% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $4.57M $1.07M +$74K +7.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.5M $1M +$800K +400% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 $3.7M $1.3M $0 0% Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-10
Q2 2020 $3.7M $1.2M -$100K -7.69% Apr 1, 2020 Jun 30, 2020 10-Q 2020-08-11
Q1 2020 $3.8M $1M -$200K -16.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $4M $200K -$1.8M -90% Oct 1, 2019 Dec 31, 2019 8-K 2021-09-08
Q3 2019 $5.8M $1.3M +$1.3M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $4.5M $1.3M +$1.3M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $3.2M $1.2M +$1.2M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $2M $2M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-19
Q3 2018 $0 Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $0 Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $0 Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.